mavorixafor   Click here for help

GtoPdb Ligand ID: 8580

Synonyms: AMD 070 | AMD-070 | AMD-11070 | AMD11070 | compound 2 [PMID: 20297846] | X4P-001 | X4P-001-IO | X4P-001-LD
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Mavorixafor (AMD070) is a potent, selective and bioavailable CXCR4 chemokine receptor allosteric antagonist [1]. Originally developed for HIV treatment, it is now being repurposed by X4 Pharmaceuticals as X4P-001 for the treatment of WHIM syndrome, a sub-type of a primary immunodeficiency disease caused by CXCR4 mutations. The compound is exemplified in a process patent US7332605 and as compound 89 from a series of 169 analogues in WO2003055876 but neither filing includes activity data.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 70.83
Molecular weight 349.23
XLogP 2.23
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NCCCCN(C1CCCc2c1nccc2)Cc1nc2c([nH]1)cccc2
Isomeric SMILES NCCCCN([C@H]1CCCc2c1nccc2)Cc1nc2c([nH]1)cccc2
InChI InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1
InChI Key WVLHHLRVNDMIAR-IBGZPJMESA-N
References
1. Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D et al.. (2010)
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
J Med Chem, 53 (8): 3376-88. [PMID:20297846]
2. Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP. (2008)
Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Mol Pharmacol, 74 (6): 1485-95. [PMID:18768385]